

ESMO PRECEPTORSHIP PROGRAMME

GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Singapore
4-5 December 2024

CHAIRS

Florian Lordick, Germany
Sun Young Rha, Republic of Korea

SPEAKERS

Hanneke van Laarhoven, the Netherlands	Hiroyuki Ono, Japan
Tony K. H. Lim, Singapore	Elizabeth Smyth, United Kingdom
Matthew C. H. Ng, Singapore	Jimmy B. Y. So, Singapore
Joanne Y. Y. Ngeow, Singapore	Wei Peng Yong, Singapore

LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) and esophageal squamous cell cancers in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localised gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localised gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations, and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event will be accredited with **ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 4 December 2024

09:30-09:40 10'	Welcome and introduction	Florian Lordick, DE Sun Young Rha, KR
09:40-11:10 90'	SESSION 1 Epidemiology, pathology and classification of gastric cancer	Chair: Sun Young Rha, KR
25'	Epidemiology, pathogenesis and staging	Florian Lordick, DE
25'	Pathology of gastric and EGJ cancer: Classification and biomarkers	Tony K. H. Lim, SG
25'	A practical approach to hereditary gastric cancers	Joanne Y. Y. Ngeow, SG
15'	Discussion	Faculty
11:10-11:40	Coffee break	
11:40-12:45 65'	SESSION 2 Treatment of early and localised gastric cancer	Chair: Florian Lordick, DE
25'	Endoscopic treatment: EMR and ESD	Hiroyuki Ono, JP
25'	Surgical approach	Jimmy B. Y. So, SG
15'	Discussion	Faculty
12:45-13:45	Lunch	
13:45-15:15 90'	SESSION 4 Perioperative strategy of localised gastric cancer	Chair: Elizabeth Smyth, UK
25'	Adjuvant treatment of gastric cancer	Sun Young Rha, KR
25'	Neo-adjuvant and perioperative concepts	Matthew C. H. Ng, SG
25'	Integration of immune-therapy and targeted therapy	Florian Lordick, DE
15'	Discussion	Faculty
15:15-15:45	Coffee break	
15:45-16:45 60'	SESSION 5 Specific situation of metastatic gastric cancer	Chair: Sun Young Rha, KR
25'	Approaches to treatment of oligometastatic disease	Hanneke van Laarhoven, NL
25'	Conversion surgery	Jimmy B. Y. So, SG
10'	Discussion	Faculty
16:45-17:15 30'	SESSION 6 Participants clinical case discussion	Chair: Matthew C. H. Ng, SG
30'	Participants clinical case discussion (2x15') (<i>locally advanced disease</i>)	Faculty
19:00	Networking dinner	

Thursday, 5 December 2024

09:00-10:30 90'	SESSION 7 Systemic treatment of metastatic gastric cancer	Chair: Wei Peing Yong, SG
25'	Standard chemotherapy and sequencing	Elizabeth Smyth, UK
25'	Immunotherapy	Sun Young Rha, KR
25'	Targeted therapy	Wei Peng Yong, SG
15'	Discussion	Faculty
10:30-11:00 Coffee break		
11:00-12:15 75'	SESSION 8 Participants clinical case discussion	Chair: Hanneke van Laarhoven, NL
75'	Participants clinical case discussion (5x15') (<i>advanced disease</i>)	Faculty
12:15-12:20 5'	Conclusion and farewell	Florian Lordick, DE Sun Young Rha, KR
12:20-13:20 Lunch		

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion